SUPN - Supernus Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
1.36B
Enterprise Value 3
1.47B
Trailing P/E
13.33
Forward P/E 1
12.93
PEG Ratio (5 yr expected) 1
0.32
Price/Sales (ttm)
3.32
Price/Book (mrq)
2.59
Enterprise Value/Revenue 3
3.58
Enterprise Value/EBITDA 6
9.63

Trading Information

Stock Price History

Beta (3Y Monthly) 1.42
52-Week Change 3-45.96%
S&P500 52-Week Change 36.81%
52 Week High 349.47
52 Week Low 325.15
50-Day Moving Average 327.35
200-Day Moving Average 331.60

Share Statistics

Avg Vol (3 month) 3536.46k
Avg Vol (10 day) 3555.2k
Shares Outstanding 552.45M
Float 50.7M
% Held by Insiders 13.36%
% Held by Institutions 198.94%
Shares Short (Sep 30, 2019) 45.58M
Short Ratio (Sep 30, 2019) 49.58
Short % of Float (Sep 30, 2019) 414.94%
Short % of Shares Outstanding (Sep 30, 2019) 410.64%
Shares Short (prior month Aug 30, 2019) 46.54M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 25.66%
Operating Margin (ttm)35.53%

Management Effectiveness

Return on Assets (ttm)9.48%
Return on Equity (ttm)22.99%

Income Statement

Revenue (ttm)409.1M
Revenue Per Share (ttm)7.82
Quarterly Revenue Growth (yoy)5.20%
Gross Profit (ttm)393.54M
EBITDA 152.29M
Net Income Avi to Common (ttm)104.97M
Diluted EPS (ttm)1.94
Quarterly Earnings Growth (yoy)6.50%

Balance Sheet

Total Cash (mrq)258.57M
Total Cash Per Share (mrq)4.93
Total Debt (mrq)368.1M
Total Debt/Equity (mrq)70.40
Current Ratio (mrq)2.71
Book Value Per Share (mrq)9.97

Cash Flow Statement

Operating Cash Flow (ttm)156.98M
Levered Free Cash Flow (ttm)127.14M